Cecilia Linde

List of Publications by Year in Descending Order

148 papers	23,592 citations	39 h-index	153 g-index
170 ext. papers	28,907 ext. citations	5.9 avg, IF	6.23 L-index

#	Paper	IF	Citations
148	Electrical management of heart failure: from pathophysiology to treatment.. *European Heart Journal*, **2022**,	9.5	5
147	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure.. *ESC Heart Failure*, **2022**,	3.7	1
146	Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population.. *Turk Kardiyoloji Dernegi Arsivi*, **2022**, 50, 182-191	0.3	
145	A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.. *European Heart Journal*, **2021**,	9.5	6
144	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. *ESC Heart Failure*, **2021**, 9, 164	3.7	1
143	Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease-A randomized controlled trial. *International Journal of Cardiology: Hypertension*, **2021**, 8, 100074	1.6	1
142	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. *Europace*, **2021**, 23, 1324-1342	3.9	4
141	Importance of Systematic Right Ventricular Assessment in Cardiac Resynchronization Therapy Candidates: A Machine Learning Approach. *Journal of the American Society of Echocardiography*, **2021**, 34, 494-502	5.8	1
140	Prognostic utility of the assessment of diastolic function in patients undergoing cardiac resynchronization therapy. *International Journal of Cardiology*, **2021**, 331, 144-151	3.2	0
139	Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. *JACC: Clinical Electrophysiology*, **2021**, 7, 871-880	4.6	4
138	Reorganization of heart failure management and improved outcome - the 4D HF Project. *Scandinavian Cardiovascular Journal*, **2021**, 55, 1-8	2	2
137	Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial. *European Heart Journal*, **2021**, 42, 4740-4742	9.5	2
136	Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score. *ESC Heart Failure*, **2021**, 8, 1827-1839	3.7	7
135	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *European Heart Journal*, **2021**, 42, 3427-3520	9.5	134
134	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study. *ESC Heart Failure*, **2021**, 8, 4243-4254	3.7	1
133	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. *Europace*, **2021**,	3.9	2
132	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. *Europace*, **2021**,	3.9	1

131	Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. *ESC Heart Failure*, **2020**, 7, 1534-1546	3.7	9
130	Myocardial micro-biopsy procedure for molecular characterization with increased precision and reduced trauma. *Scientific Reports*, **2020**, 10, 8029	4.9	3
129	Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry". *Circulation*, **2020**, 141, e648-e649	16.7	1
128	Increased iron absorption in patients with chronic heart failure and iron deficiency. *Journal of Cardiac Failure*, **2020**, 26, 440-443	3.3	2
127	The transition from hypertension to hypertensive heart disease and heart failure: the PREFERS Hypertension study. *ESC Heart Failure*, **2020**, 7, 737-746	3.7	13
126	Future research prioritization in cardiac resynchronization therapy. *American Heart Journal*, **2020**, 223, 48-58	4.9	7
125	Circulating neuregulin1-β in heart failure with preserved and reduced left ventricular ejection fraction. *ESC Heart Failure*, **2020**, 7, 445-455	3.7	5
124	Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. *Europace*, **2020**, 22, 932-938	3.9	0
123	Cardiac resynchronization therapy in Romania – results from the European Society of Cardiology CRT Survey II. *Revista Romana De Cardiologie*, **2020**, 30, 48-55	0.1	1
122	Current clinical practice of cardiac resynchronization therapy in Turkey: Reflections from Cardiac Resynchronization Therapy Survey-II. *Anatolian Journal of Cardiology*, **2020**, 24, 382-396	0.8	1
121	Second European Cardiac Resynchronisation Therapy Survey (Crt Survey Ii): Latvian Data Compared to Europe. *Proceedings of the Latvian Academy of Sciences*, **2020**, 74, 358-365	0.3	
120	Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II. *Clinical Research in Cardiology*, **2020**, 109, 832-844	6.1	2
119	Quality of life with implanted devices **2020**, 893-900		
118	Metabolomic Profile in HFpEF vs HFrEF Patients. *Journal of Cardiac Failure*, **2020**, 26, 1050-1059	3.3	11
117	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. *European Journal of Heart Failure*, **2020**, 22, 2349-2369	12.3	38
116	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. *Journal of Cardiovascular Medicine*, **2020**, 21, 634-640	1.9	0
115	The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease. *European Heart Journal*, **2020**, 41, 3113-3116	9.5	2
114	Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance. *European Heart Journal*, **2020**, 41, 3813-3823	9.5	20

113	Benchmarking Belgian CRT practice against the rest of Europe: insights from the ESC-CRT survey II. *Acta Cardiologica*, **2020**, 75, 492-496	0.9	
112	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. *Journal of Cardiac Failure*, **2020**, 26, 673-684	3.3	2
111	Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. *European Heart Journal Quality of Care & Clinical Outcomes*, **2020**, 6, 147-155	4.6	1
110	Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21´334 patients in the UK. *ESC Heart Failure*, **2019**, 6, 280-290	3.7	30
109	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. *Circulation*, **2019**, 140, 1530-1539	16.7	41
108	The Membership Committee of the ESC. *Cardiovascular Research*, **2019**, 115, e130-e132	9.9	
107	Sex-Related Procedural Aspects and Complications in CRT Survey II: A Multicenter European Experience in 11,088 Patients. *JACC: Clinical Electrophysiology*, **2019**, 5, 1048-1058	4.6	7
106	The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. *BMC Nephrology*, **2019**, 20, 31	2.7	14
105	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. *ESC Heart Failure*, **2019**, 6, 830-839	3.7	6
104	Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction. *Scientific Reports*, **2019**, 9, 3179	4.9	22
103	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. *International Journal of Cardiology*, **2019**, 287, 66-72	3.2	8
102	Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). *Revista Espanola De Cardiologia (English Ed)*, **2019**, 72, 1020-1030	0.7	
101	Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. *Europace*, **2019**, 21, 918-927	3.9	6
100	Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. *International Journal of Cardiology*, **2019**, 274, 202-207	3.2	8
99	Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. *Journal of the American Heart Association*, **2019**, 8, e012655	6	18
98	The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France. *Archives of Cardiovascular Diseases*, **2019**, 112, 713-722	2.7	
97	Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II Registry. *Kardiologia Polska*, **2019**, 77, 40-46	0.9	2
96	Contemporary practice of CRT implantation in scandinavia compared to Europe. *Scandinavian Cardiovascular Journal*, **2019**, 53, 9-13	2	1

95	ST2 in heart failure with preserved and reduced ejection fraction. *Scandinavian Cardiovascular Journal*, **2019**, 53, 21-27	2	25
94	Cardiac resynchronization in Poland - comparable procedural routines? Insights from CRT Survey II. *Postepy W Kardiologii Interwencyjnej*, **2019**, 15, 477-484	0.4	
93	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how?. *European Journal of Heart Failure*, **2018**, 20, 1039-1051	12.3	65
92	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. *European Journal of Heart Failure*, **2018**, 20, 780-791	12.3	47
91	The year in cardiology 2017: arrhythmias and cardiac devices. *European Heart Journal*, **2018**, 39, 434-441	9.5	3
90	Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines. *JACC: Heart Failure*, **2018**, 6, 308-316	7.9	47
89	Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. *American Journal of Cardiology*, **2018**, 121, 1558-1566	3	8
88	Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions. *Europace*, **2018**, 20, 908-920	3.9	20
87	Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. *BMC Nephrology*, **2018**, 19, 211	2.7	24
86	Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis. *Kardiologia Polska*, **2018**, 76, 107-118	0.9	30
85	Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. *Swiss Medical Weekly*, **2018**, 148, w14643	3.1	1
84	FP371RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD. *Nephrology Dialysis Transplantation*, **2018**, 33, i157-i157	4.3	
83	FP337RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD. *Nephrology Dialysis Transplantation*, **2018**, 33, i145-i145	4.3	0
82	Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry. *Cardiology Research and Practice*, **2018**, 2018, 3479846	1.9	1
81	Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries. *Scandinavian Cardiovascular Journal*, **2018**, 52, 348-355	2	6
80	Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. *Journal of Medical Economics*, **2018**, 21, 1172-1182	2.4	2
79	Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. *International Journal of Cardiology*, **2018**, 267, 128-132	3.2	19
78	Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. *Europace*, **2018**, 20, 1565-1565ao	3.9	108

77	New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy. *European Journal of Heart Failure*, **2017**, 19, 366-376	12.3	21
76	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach. *Circulation: Cardiovascular Genetics*, **2017**, 10,		56
75	Effects of Spinal Cord Stimulation on Cardiac Sympathetic Nerve Activity in Patients with Heart Failure. *PACE - Pacing and Clinical Electrophysiology*, **2017**, 40, 504-513	1.6	9
74	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial. *JACC: Heart Failure*, **2017**, 5, 169-178	7.9	22
73	The burden of proof: The current state of atrial fibrillation prevention and treatment trials. *Heart Rhythm*, **2017**, 14, 763-782	6.7	23
72	Spinal cord stimulation in heart failure: effect on disease-associated biomarkers. *European Journal of Heart Failure*, **2017**, 19, 283-286	12.3	5
71	Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2017**, 19, 1270-1279	12.3	54
70	HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. *International Journal of Cardiology*, **2017**, 228, 709-716	3.2	27
69	The Impact of the PR Interval in Patients Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study. *JACC: Clinical Electrophysiology*, **2017**, 3, 818-826	4.6	3
68	Predictors of short-term clinical response to cardiac resynchronization therapy. *European Journal of Heart Failure*, **2017**, 19, 1056-1063	12.3	18
67	The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study. *Heart and Vessels*, **2017**, 32, 735-749	2.1	5
66	Cardiac Resynchronization Therapy Follow-up: Role of Remote Monitoring. *Heart Failure Clinics*, **2017**, 13, 241-251	3.3	3
65	Spatial detection of fetal marker genes expressed at low level in adult human heart tissue. *Scientific Reports*, **2017**, 7, 12941	4.9	36
64	Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis. *Medical Science Monitor Basic Research*, **2017**, 23, 179-222	3.2	30
63	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. *International Journal of Cardiology*, **2017**, 226, 65-70	3.2	3
62	HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. *Journal of Cardiac Failure*, **2017**, 23, 293-303	3.3	21
61	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Europace*, **2017**, 19, 1556-1578	3.9	137
60	Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants. *European Journal of Heart Failure*, **2016**, 18, 1287-1297	12.3	11

59	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. *JACC: Heart Failure*, **2016**, 4, 129-136	7.9	60
58	Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. *International Journal of Cardiology*, **2016**, 202, 349-55	3.2	20
57	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, **2016**, 37, 2129-2200	9.5	7751
56	Improvement of blood pressure control and physiciansR management over time in patients with coronary artery disease. *Blood Pressure*, **2016**, 25, 286-91	1.7	1
55	Cardiac resynchronization therapy: results, challenges and perspectives for the future. *Scandinavian Cardiovascular Journal*, **2016**, 50, 282-292	2	3
54	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Journal of Heart Failure*, **2016**, 18, 891-975	12.3	4036
53	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. *European Journal of Heart Failure*, **2015**, 17, 135-43	12.3	15
52	Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials. *JACC: Heart Failure*, **2015**, 3, 327-36	7.9	21
51	Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. *International Journal of Cardiology*, **2015**, 189, 6-11	3.2	14
50	Increase in paced heart rate reduces muscle sympathetic nerve activity in heart failure patients treated with cardiac resynchronization therapy. *Europace*, **2015**, 17, 439-46	3.9	5
49	Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. *European Heart Journal*, **2015**, 36, 2780-9	9.5	39
48	Cardiac Resynchronization Therapy Follow-up: Role of Remote Monitoring. *Cardiac Electrophysiology Clinics*, **2015**, 7, 797-807	1.4	6
47	Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. *Open Heart*, **2015**, 2, e000260	3	13
46	The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?. *European Heart Journal*, **2015**, 36, 1676-88	9.5	16
45	Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. *Europace*, **2015**, 17, 424-31	3.9	39
44	New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. *European Journal of Heart Failure*, **2015**, 17, 680-8	12.3	56
43	Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). *Journal of the American Heart Association*, **2015**, 4, e002054	6	21
42	European cardiac resynchronization therapy survey II: rationale and design. *Europace*, **2015**, 17, 137-41	3.9	19

41	The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. *Heart Rhythm*, **2015**, 12, 524-530	6.7	66
40	Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry. *Europace*, **2015**, 17, 69-77	3.9	71
39	Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2014**, 16, 992-1001	12.3	93
38	Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. *Archives of Cardiovascular Diseases*, **2014**, 107, 112-21	2.7	34
37	Current challenges for clinical trials of cardiovascular medical devices. *International Journal of Cardiology*, **2014**, 175, 30-7	3.2	31
36	Trials of implantable monitoring devices in heart failure: which design is optimal?. *Nature Reviews Cardiology*, **2014**, 11, 576-85	14.8	27
35	Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14,713 patients in the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2014**, 16, 1073-81	12.3	32
34	Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. *European Heart Journal*, **2013**, 34, 2592-9	9.5	110
33	An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. *European Heart Journal*, **2013**, 34, 3547-56	9.5	297
32	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. *Circulation: Heart Failure*, **2013**, 6, 1180-9	7.6	25
31	2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Europace*, **2013**, 15, 1070-118	3.9	731
30	Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. *European Heart Journal*, **2013**, 34, 529-39	9.5	98
29	Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 1163-8	6.4	43
28	Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. *European Journal of Heart Failure*, **2013**, 15, 1419-28	12.3	26
27	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *European Heart Journal*, **2013**, 34, 2281-329	9.5	1491
26	Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. *Circulation*, **2012**, 126, 822-9	16.7	215
25	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. *Europace*, **2012**, 14, 1236-86	3.9	195
24	Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations. *Heart Rhythm*, **2012**, 9, S3-S13	6.7	69

23	Cardiac resynchronization therapy in patients with New York Heart Association class I and II heart failure: an approach to 2010. *Circulation*, **2010**, 122, 1037-43	16.7	15
22	Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. *Journal of the American College of Cardiology*, **2010**, 56, 1826-31	15.1	72
21	The European cardiac resynchronization therapy survey. *European Heart Journal*, **2009**, 30, 2450-60	9.5	178
20	Cardiac resynchronization therapy in mild heart failure. *Europace*, **2009**, 11 Suppl 5, v72-6	3.9	5
19	Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2009**, 11, 198-204	12.3	39
18	Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. *Journal of the American College of Cardiology*, **2009**, 54, 1837-46	15.1	260
17	Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. *Congestive Heart Failure*, **2008**, 14, 66-74		23
16	Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *Journal of the American College of Cardiology*, **2008**, 52, 1834-1843	15.1	851
15	Future directions in cardiac resynchronization therapy. *Current Heart Failure Reports*, **2008**, 5, 51-5	2.8	
14	History of electrical therapy for the heart. *Country Review Ukraine*, **2007**, 9, I3-I10		19
13	Cardiac resynchronization therapy: clinical results and evolution of candidate selection. *Country Review Ukraine*, **2007**, 9, I94-I106		7
12	Celebrating 50 years of electrical therapies for the heart. *Country Review Ukraine*, **2007**, 9, I1-I2		1
11	Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. *American Heart Journal*, **2006**, 151, 288-94	4.9	68
10	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *European Heart Journal*, **2005**, 26, 1115-40	9.5	1642
9	Implantable cardioverter-defibrillator treatment and resynchronisation in heart failure. *British Heart Journal*, **2004**, 90, 231-4		5
8	Long-term improvements in quality of life by biventricular pacing in patients with chronic heart failure: results from the Multisite Stimulation in Cardiomyopathy study (MUSTIC). *American Journal of Cardiology*, **2003**, 91, 1090-5	3	103
7	Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. *Journal of the American College of Cardiology*, **2002**, 40, 111-8	15.1	721
6	Combipolar sensing in dual chamber pacing: is there still a need for bipolar leads in the atrium?. *PACE - Pacing and Clinical Electrophysiology*, **2001**, 24, 1664-71	1.6	1

5	Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *New England Journal of Medicine*, **2001**, 344, 873-80	59.2	2212
4	Reduction of hospital days by biventricular pacing. *European Journal of Heart Failure*, **2000**, 2, 399-406	12.3	40
3	Women and arrhythmias. *PACE - Pacing and Clinical Electrophysiology*, **2000**, 23, 1550-60	1.6	10
2	Quality-of-life in pacemaker and implantable cardioverter defibrillator recipients. *PACE - Pacing and Clinical Electrophysiology*, **2000**, 23, 931-3	1.6	4
1	Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. *American Journal of Cardiology*, **1999**, 83, 903-7	3	129